Showing 5491-5500 of 8839 results for "".
- Visible Light from the Sun Causes Pigmentary Skin Changeshttps://practicaldermatology.com/news/visible-light-from-the-sun-causes-pigmentary-skin-changes/2460768/Visible light from the sun plays a significant role in causing pigmentary skin changes, particularly in people with skin of color, according to information presented at AAD VMX 2021. “We know from decades of research that unprotected exposure to ultraviolet light from the sun can
- Leo Pharma’s Tralokinumab Produces Sustained Improvement in ADhttps://practicaldermatology.com/news/leo-pharmas-tralokinumab-produces-sustained-improvement-in-ad/2460766/Leo Pharma’s tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) showed long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms, according to an interim analysis at 56 weeks in the ECZTEND trial that was presented at the AAD
- Data Show Long-term Safety, Clinical Benefit of Dupilumab in Pediatric ADhttps://practicaldermatology.com/news/data-show-long-term-safety-clinical-benefit-of-dupilumab-in-pediatric-ad/2460757/Dupilumab (Dupixent, Sanofi/Regeneron) is safe and effective for the long-term management of atopic dermatitis in patients as young as six, data from a collection of posters presented at the AAD 2021 VMX show. One study
- Research Reveals How Skin May Repair Itselfhttps://practicaldermatology.com/news/research-reveals-how-skin-may-repair-itself/2460755/Activation of two transcription factors may enhance a natural process of skin cell division, a desirable outcome in regenerative medicine, according to a study in Nucleic Acid Research. In normal conditions, one in every four cells isolated from the inner layer of the skin
- First Launch from FlawlessCanvas Now Availablehttps://practicaldermatology.com/news/first-launch-from-flawlesscanvas-now-available/2460750/Quantum Lift Reset Serum™ is now available from FlawlessCanvas, Inc., direct to its Facebook and Instagram followers. “The design of FlawlessCanvas Quantum Lift Reset Serum™ was based on
- ASDSA Alerts Nation’s Governors to New Trend in Anti-transgender Legislationhttps://practicaldermatology.com/news/asdsa-alerts-nations-governors-to-new-trend-in-anti-transgender-legislation/2460749/The American Society for Dermatologic Surgery Association (ASDSA) sent a letter to all 50 state governors along with legislative leaders, alerting them to the increase in anti-transgender legislation that is proliferating in state legislatures across the country. After Arkansas be
- Hydrafacial Expands CONNECT Certification Programhttps://practicaldermatology.com/news/hydrafacial-expands-connect-certification-program/2460733/The HydraFacial Company is expanding the HydraFacial CONNECT certification program, making it available to aesthetic professionals nationwide. This past month, the program successfully graduated its first class of CONNECT Masters, the highest distinction in the certification progr
- AAD Honors Dr. Ginette Okoye with National Patient Care Hero Award for COVID-19 Testing Workhttps://practicaldermatology.com/news/aad-honors-dr-ginette-okoye-with-national-patient-care-hero-award-for-covid-19-testing-work/2460729/The American Academy of Dermatology (AAD) named board-certified dermatologist Ginette Okoye, MD, FAAD a Patient Care Hero for establishing a dedicated COVID-19 community testing site in a historically underserved neighborhood in northeast Washington, DC. Amid the initial surge in COVID-
- SkinKick Launches Acne System at Ulta Beautyhttps://practicaldermatology.com/news/skinkick-launches-acne-system-at-ulta-beauty/2460725/SkinKick’s Acne KickPRO™ Duo is the brand’s first Ulta Beauty™ exclusive. The two-step homeopathic treatment for acute acne, began rolling out in February at Ulta Beauty online and in-stores nationwide. SkinKick is a pa
- Aditxt to Initiate First In-Human Clinical Trials with its Therapeutics Programs in Psoriasishttps://practicaldermatology.com/news/aditxt-to-initiate-first-in-human-clinical-trials-with-its-therapeutics-programs-in-psoriasis/2460724/Aditx Therapeutics, Inc.’s AditxtReprogramming Therapeutics Division is preparing its to begin first-in-human clinical